TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17559990
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) administration of 15, 30, or 60mcg of trivalent inactivated influenza vaccine
Study: 17559990
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of 15, 30, or 60mcg of trivalent inactivated influenza vaccine
Study: 17559990
Drug: Combined IM
Normalized name: AUTOLOGOUS CD34+ CELLS ISOLATED FROM BONE MARROW OF NEWLY DIAGNOSED X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (X-SCID) PATIENTS, TRANSDUCED EX VIVO WITH A SELF-INACTIVATING LENTIVIRAL VECTOR, ENCODING CODON-OPTIMIZED HUMAN INTERLEUKIN-2 RECEPTOR SUBUNIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IM and IN administration of trivalent inactivated influenza vaccine
Study: 3655856
Drug: CAF chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF chemotherapy (cyclophosphamide + doxorubicin + 5‐fluorouracil [5‐FU])
Study: 3655856
Drug: CAF chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF chemotherapy (for ER+ patients)
Study: 3655856
Drug: CAF chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF chemotherapy (for ER- patients)
Study: 29023249
Drug: 1-Hz repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-Hz repetitive transcranial magnetic stimulation (rTMS) over contralesional leg motor cortex for 15 minutes followed by 45 minutes of physical therapy for 15 sessions over 3 weeks
Study: 29023249
Drug: Sham 1-Hz
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham 1-Hz repetitive transcranial magnetic stimulation (rTMS) over contralesional leg motor cortex for 15 minutes followed by 45 minutes of physical therapy for 15 sessions over 3 weeks
Study: 24172209
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran ER (40 to 120 mg/d)
Study: 20155988
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg/day (monotherapy)
Study: 20155988
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg/day with pravastatin 10 mg/day
Study: 20155988
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg/day with rosuvastatin 2.5 mg/day
Study: 20155988
Drug: ezetimibe (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe (both monotherapy and combination therapy)
Study: 11919665
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg on days 1-8, 100 mg on days 9-15)
Study: 11919665
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg on days 1-8, 40 mg on days 9-15)
Study: 10344359
Drug: Hb concentration
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hb concentration of 14 g/dl ([Hb]14)
Study: 10344359
Drug: Hb concentration
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hb concentration of 10 g/dl ([Hb]10)
Study: 2035006
Drug: Salt loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt loading (+6.1 +/- 2.8 g NaCl/d = 105 +/- 48 mmol Na)
Study: 2035006
Drug: Loading with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading with sodium citrate in equimolar concentrations (+140 +/- 40 ml Shohl's solution = 120 +/- 34 mmol Na)
Study: 7237927
Drug: Low cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low cholesterol fat-modified diet (mean 200 mg/day, polyunsaturated/saturated fat ratio of 1.0, 43% of total energy from fat)
Study: 31779672
Drug: Cryo-RDN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryo-RDN treatment
Study: 31779672
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (renal angiography alone)
Study: 22077869
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 400 mg
Study: 9594474
Drug: Nonvital pulp
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonvital pulp treatment
Study: 7983882
Drug: Leukocyte-depleted terminal
Normalized name: Terminator
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leukocyte-depleted terminal cardioplegic solution (n = 10)
Study: 7983882
Drug: Terminal cardioplegic
Normalized name: Terminator
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terminal cardioplegic solution (n = 10)
Study: 29806665
Drug: 6 mm
Normalized name: I-Port, 6 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mm long × 4 mm wide implants
Study: 29806665
Drug: Implants of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants of at least 10 mm long
Study: 29065426
Drug: FOLFOX-4 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-4 or XELOX adjuvant chemotherapy
Study: 17914655
Drug: argon plasma
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: argon plasma coagulation plus imiquimod cream
Study: 17914655
Drug: HIV-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-positive patients with combination therapy
Study: 17914655
Drug: HIV-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-positive patients with monotherapy
Study: 14681347
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort (SJW) 300 mg three times a day for 15 days
Study: 14681347
Drug: Theophylline 400
Normalized name: theophylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 400 mg single oral dose
Study: 11010695
Drug: Gender, limitations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender, limitations in daily living activities, dementia, and utilization of services
Study: 9403274
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil (ME1207) 50 mg
Study: 9403274
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil (ME1207) 100 mg
Study: 9403274
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil (ME1207) 200 mg
Study: 9403274
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil (ME1207) 300 mg
Study: 9403274
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil (ME1207) 500 mg
Study: 9403274
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil (ME1207) 200 mg after a meal
Study: 9403274
Drug: Cefditoren pivoxil
Normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefditoren pivoxil (ME1207) 200 mg every 12 h for 7 days
Study: 3548954
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (chronic phase)
Study: 3548954
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (acute phase)
Study: 3548954
Drug: Intramuscular placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular placebo (acute phase)
Study: 30561029
Drug: Psyllium group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium group (Mucilin SF 15.2 g/L added to Blendera)
Study: 15082421
Drug: Palm oil
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palm oil infusion
Study: 15082421
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil infusion
Study: 10453752
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (DSCG non-treated patients)
Study: 7884019
Drug: Doxepin 150
Normalized name: doxepin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 150 mg per day
Study: 3067744
Drug: Carteolol 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 2% twice daily
Study: 18795647
Drug: CPC/ZG gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPC/ZG gel (0.10% cetylpyridinium chloride and 0.592% zinc gluconate)
Study: 18795647
Drug: Control gel
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control gel (0% CPC and 0.592% ZG)
Study: 16636029
Drug: Doxapram hydrochloride
Normalized name: Doxapram Hydrochloride
DrugBank: Doxapram (DB00561)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxapram hydrochloride 1 mg.kg(‐1) iv
Study: 12100930
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2% lidocaine gel intrarectally
Study: 12100930
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 1% lidocaine solution periprostatic injection
Study: 2328553
Drug: WEB-2086 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEB-2086 (40 mg)
Study: 6931307
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy containing MeCCNU
Study: 30985546
Drug: Maternal viral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal viral load >10,000 copies/mL
Study: 30985546
Drug: Maternal viral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal viral load <1000 copies/mL
Study: 30985546
Drug: Maternal viral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal viral load 1000.1-10,000 copies/mL
Study: 23896581
Drug: 2010-2011 seasonal
Normalized name: seasonal influenza, intradermal, preservative free syringe 2011-2012 [FLUZONE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by GlaxoSmithKline
Study: 23896581
Drug: 2010-2011 seasonal
Normalized name: seasonal influenza, intradermal, preservative free syringe 2011-2012 [FLUZONE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by Sanofi Pasteur
Study: 23896581
Drug: 2010-2011 seasonal
Normalized name: seasonal influenza, intradermal, preservative free syringe 2011-2012 [FLUZONE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by Sinovac Biotech
Study: 23896581
Drug: 2010-2011 seasonal
Normalized name: seasonal influenza, intradermal, preservative free syringe 2011-2012 [FLUZONE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2010-2011 seasonal trivalent influenza vaccine (TIV)
Study: 19706087
Drug: Combination bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination bathing and emollient application regimens
Study: 25687540
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin application
Study: 25990305
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of MRA therapy (potassium canrenoate 200 mg) followed by oral spironolactone 50 mg once daily for 3 months
Study: 15552355
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation of items for selection
Study: 9371930
Drug: Optic neuritis
Normalized name: Opti-Nail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optic neuritis treatment
Study: 1287831
Drug: Heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuit with 50% reduction of systemic heparin bolus
Study: 1287831
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard heparin treatment)
Study: 12281505
Drug: hCG injections
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injections (250 IU/day i.m.) for 21 days in OC users
Study: 12281505
Drug: hCG injections
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG injections (250 IU/day i.m.)
Study: 29097325
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg dezocine
Study: 29097325
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg dezocine
Study: 29097325
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg dezocine
Study: 29097325
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.1 mg/kg)
Study: 24057149
Drug: Intravenous amantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amantadine
Study: 21463139
Drug: Docetaxel-based therapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel-based therapy
Study: 21192296
Drug: Standard exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard exercise therapy
Study: 9327311
Drug: fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl infusion + diazepam + sodium nitroprusside (SNP)
Study: 9327311
Drug: fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl infusion + isoflurane
Study: 9327311
Drug: fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl infusion + diazepam
Study: 7968323
Drug: Vecuronium with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium with a priming dose of 0.1 mg/kg followed by 0.09 mg/kg (Gp1)
Study: 7968323
Drug: Vecuronium with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium with a priming dose of 0.1 mg/kg followed by 0.14 mg/kg (Gp2)
Study: 7968323
Drug: Vecuronium with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium with a priming dose of 0.1 mg/kg followed by 0.19 mg/kg (Gp3)
Study: 7968323
Drug: Vecuronium without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium without a priming dose followed by 0.1 mg/kg (Gp4)
Study: 7968323
Drug: Vecuronium without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium without a priming dose followed by 0.15 mg/kg (Gp5)
Study: 7968323
Drug: Vecuronium without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium without a priming dose followed by 0.2 mg/kg (Gp6)
Study: 28190719
Drug: Three-component smoking
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-component smoking cessation intervention (physician advice, nicotine replacement therapy, and telephone-based quitline referral)
Study: 26227096
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg linezolid infusion over 0.5 hours
Study: 26227096
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg linezolid infusion over 2 hours
Study: 26227096
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg linezolid infusion over 4 hours
Study: 24119833
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg by mouth
Study: 21091391
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin (PRM; Circadin 2 mg)
Study: 19176534
Drug: Antepartum continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antepartum continuous epidural therapy (ACET) with 0.04, 0.06, 0.08, and 0.1% ropivacaine at 10 ml h(‐1) for 24 h.
Study: 19176534
Drug: Antepartum continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antepartum continuous epidural therapy (ACET) with 0.1% ropivacaine until delivery.
Study: 18173095
Drug: OP-lycopene (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP-lycopene (8 mg lycopene/day for 2 weeks)
Study: 18173095
Drug: non-OP-lycopene (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-OP-lycopene (8 mg lycopene/day for 2 weeks)
Study: 15469204
Drug: Quetiapine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (50 mg/day titrated to 500 mg/day, maintained or increased to 750 mg/day)
Study: 12804167
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (specifics not provided)
Study: 2181623
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine twice daily
Study: 2096128
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg cimetidine once daily (bedtime)
Study: 25335860
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of netazepide and rabeprazole
Study: 21258269
Drug: Depressive symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depressive symptoms and drug use before sex
Study: 19681775
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids solution (Control Group)
Study: 15479889
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care physical therapy (UC)
Study: 7605232
Drug: Quinidine (QG)
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine (QG) - i.v. digital + quinidine up to 600 mg
Study: 7605232
Drug: Procainamide (PG)
Normalized name: PG-530742
DrugBank: Procainamide (DB01035)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procainamide (PG) - i.v. digital + i.v. procainamide, 10 mg/kg
Study: 7605232
Drug: Amiodarone (AG)
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone (AG) - i.v. amiodarone, 5 mg/kg
Study: 30207488
Drug: Enzalutamide after
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide after chemotherapy
Study: 30207488
Drug: Enzalutamide after
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide after chemotherapy in abiraterone-pretreated patients
Study: 30207488
Drug: Enzalutamide after
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide after chemotherapy in abiraterone-naive patients
Study: 18573775
Drug: Self-administered decision
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered decision aid (DA) booklet about outcomes of biennial faecal occult blood testing (FOBT) screening
Study: 18573775
Drug: Government consumer
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Government consumer guidelines (G)
Study: 18573775
Drug: Self-administered decision
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered decision aid (DA)
Study: 10678548
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg once daily (group 1)
Study: 10678548
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg once daily plus benazepril 5 or 10 mg once daily (group 2)
Study: 10678548
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg once daily plus benazepril 5 or 10 mg once daily (group 3)
Study: 19663597
Drug: Paromomycin 11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin 11 mg/kg/day for 14 days (Group A)
Study: 19663597
Drug: Paromomycin 11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin 11 mg/kg/day for 21 days (Group B)
Study: 16728716
Drug: Low-dose ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose ethanol (0.5 g/kg body weight per day)
Study: 16728716
Drug: Morphine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (15 mug/kg body weight per hour)
Study: 16728716
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg four times daily)
Study: 15298657
Drug: Paroxetine 20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20-50 mg/day
Study: 11736682
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg ropivacaine
Study: 11736682
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg ropivacaine
Study: 11736682
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg ropivacaine
Study: 11736682
Drug: 1-3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 mg/kg ropivacaine
Study: 8564629
Drug: Salmeterol, 50
Normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 50 micrograms, dry powder inhalation
Study: 31208690
Drug: MoodKit (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoodKit (active control cognitive-behavioral therapy-based mobile app)
Study: 31208690
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; no app)
Study: 23691965
Drug: SNRI compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNRI compounds
Study: 19140909
Drug: Dofetilide therapy
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dofetilide therapy
Study: 2166142
Drug: Cyclophosphamide, doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy
Study: 2166142
Drug: Vindesine and
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine and cisplatin (VP) chemotherapy
Study: 364409
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg per day for 2 months)